Theranostics: A Living Archive of Convergence
We note background as a critical context for evaluating evidence and timelines.
Welcome to Nova TheraNostics, an independent editorial archive dedicated to the scientific and historical evolution of theranostics—the integrated approach that combines diagnosis and therapy into a single, patient-centered discipline. From the earliest experiments with radioiodine for thyroid disease to today’s sophisticated radioligand therapies and theranostic pairs, we chronicle the milestones, controversies, and conceptual shifts that have shaped this field. Our editorial team is composed of industry veterans with deep experience spanning startup ventures, big pharma, academic research, and clinical radiology. We operate with a lean, predominantly virtual structure that minimizes overhead and allows us to invest resources into rigorous curation and original commentary. This is not a static repository; it is a living publication, updated as new discoveries reframe old narratives.
Curated Reference Material & Timelines
Our core offering is a meticulously maintained collection of reference materials that trace the theranostic journey across decades and continents. We produce annotated bibliographies of landmark papers—from the first descriptions of target-specific radiopharmaceuticals to modern regulatory approvals for agents like Lu-177 DOTATATE and PSMA-targeted therapies. Each timeline is built from primary sources, including patent filings, clinical trial registrations, and FDA or EMA decision documents, contextualized by our editors to highlight inflection points and dead ends. Whether you are a researcher seeking the original dose-escalation data for a particular compound or a student mapping the shift from empirical iodine therapy to precision dosimetry, our timelines provide a structured path through the literature. We also publish periodic “Historical Notes” that revisit forgotten studies whose insights are only now being rediscovered.
Educational Scope for Practitioners and Historians
Our audience spans nuclear medicine physicians, radiochemists, medical physicists, oncology fellows, and science historians. We strive to serve both the clinician who needs a concise record of why a given tracer entered practice and the historian who pores over the social and institutional forces that accelerated or hindered theranostic adoption. Our content is peer-reviewed by a rotating board of active researchers, but we maintain editorial independence—we do not accept pharmaceutical funding or place content under sponsor control. The virtual structure of our organization means that every dollar goes toward database subscriptions, server costs, and modest honoraria for contributors, not toward real estate or administrative bloat. Readers can explore the full editorial philosophy, meet our team of industry veterans, and understand our governance by visiting the page that explains our operational model: learn more about our editorial team and operational philosophy on our About Us page.
Navigating Our Archive
The archive is organized by therapeutic area (neuroendocrine, prostate, thyroid, bone metastases), by modality (SPECT, PET, alpha-emitters, beta-emitters), and by historical period (pre-1970 foundations, 1970–1990 clinical expansion, 2000s molecular revolution, and the contemporary era of combination immunotheranostics). Each section includes a featured timeline, a curated reading list, and a “What’s New” feed that flags recent updates. Our search tools allow filtering by year, author, institution, and compound. We also host a moderated discussion forum where subscribers can submit corrections, add references, or propose new timelines—all contributions are reviewed by our editorial staff. As a living archive, we revise and expand entries as trials mature and regulatory decisions emerge. We invite you to explore the convergences that have made theranostics one of the most intellectually rich and clinically promising domains in modern medicine.
That said, claimants should organize records, treatment chronology, and exposure evidence before legal intake. Compliance terms: FDA; statute of limitations; class action; MDL; mass tort; plaintiff; settlement; adverse event; litigation; compensation.